Evidence method
Level · gp.fundamentals.debt_to_revenue
744.70% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
BBIO · Sep 30, 2026
BridgeBio Pharma, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001743881-26-000034General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.08% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-12.51% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Yoy · gp.fundamentals.revenue
192.60% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
16.91% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
94.21% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-3.30% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
40.63% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
11.29% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History1 statesHistory building
Period transition
What moved in the state?
- Previous
- 1088.69%
- Current
- 744.70%
- Delta
- -343.99%
- Previous
- 0.18%
- Current
- 0.08%
- Delta
- -0.10%
- Previous
- -29.18%
- Current
- -12.51%
- Delta
- 16.67%
- Previous
- 120.39%
- Current
- 192.60%
- Delta
- 72.21%
- Previous
- 21.69%
- Current
- 16.91%
- Delta
- -4.78%
- Previous
- 93.83%
- Current
- 94.21%
- Delta
- 0.38%
- Previous
- -43.94%
- Current
- -3.30%
- Delta
- 40.65%
- Previous
- 61.33%
- Current
- 40.63%
- Delta
- -20.70%
- Previous
- 18.27%
- Current
- 11.29%
- Delta
- -6.99%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Compared To · Pharmaceutical Preparations peers →Derived From · BBIO Company Quality Vector →Has State · BridgeBio Pharma, Inc. →Transitioned To · BBIO BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · BBIO CAPEX_INTENSITY_DECREASED →Transitioned To · BBIO CASH_GENERATION_INCREASED →Transitioned To · BBIO GROWTH_INCREASED →Transitioned To · BBIO INVENTORY_PRESSURE_DECREASED →Transitioned To · BBIO MARGIN_INCREASED →Transitioned To · BBIO PROFITABILITY_INCREASED →Transitioned To · BBIO R_AND_D_INTENSITY_DECREASED →Transitioned To · BBIO SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.